1. Scrip
  2. >>Focus On Asia
  3. >>Japan

Taisho To Go Private To Aid 'Dynamic' Restructuring, R&D Investment

$4.8bn MBO Japan's Largest

 
• By Lisa Takagi

The largest shareholder in major Japanese pharma firm Taisho, the founding Uehara family, intends to smooth the way to the restructuring and expansion of the business by acquiring and delisting all of its stock. The nearly $5bn size of the deal would makes it the biggest management buyout in Japanese corporate history.

By privatizing the firm, Taisho aims to implement several measures that would upset the firm's finance for an instant.
Taisho aims to progress business, R&D through take-private move • Source: Shutterstock

Taisho Pharmaceutical Holdings, which owns one of Japan’s largest pharmaceutical firms, over-the-counter focused Taisho Pharmaceutical Co., Ltd., initiated in late November what is set to be the largest management buyout (MBO) in the country’s corporate history, worth close to $5bn.

The founding Uehara family, which holds the single-largest combined stake in the company, has said it is seeking the take-private...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

More from Focus On Asia